Skin Aging
Conditions
Interventions
This investigation will be an interventional, randomized, two-arm, parallel, and double-blind clinical trial. Group A will receive a treatment composed of PDRN (polydeoxyribonucleotide) combined with
D13.695.578.500
Sponsors
Universidade Estadual de Montes Claros
Universidade Estadual de Montes Claros
Eligibility
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients of both sexes; diagnosed with facial sagging will be included in the study; aged between 20 and 80 years; and who have no contraindications for facial volumization procedures
Exclusion criteria
Exclusion criteria: Patients with a history of photosensitivity; keloids; hypertrophic scars; and post-inflammatory hyperpigmentation; as well as those who are pregnant or lactating; will be excluded from the study; Individuals with local inflammatory skin disorders or active herpes infection at the procedure site will also be excluded; as well as individuals with a history of medical conditions that contraindicate the procedures; such as intolerance to the components; urticaria; Raynaud's disease; or a history of allergic reactions to the components; Finally; patients who do not agree to participate in the study will also be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and efficacy of the combination of Polydeoxyribonucleotide and Growth Factors | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome of this study will address molecular changes in the tissue expression of collagen 1 and 3. This aspect aims to analyze the molecular mechanisms underlying the observed changes in skin pigmentation, seeking to better understand the biochemical pathways and cellular processes involved in the regulation of collagen production. | — |
Countries
Brazil
Contacts
Public ContactAndre Guimarães
Universidade Estadual de Montes Claros
Outcome results
None listed